Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV 1 .

MLA

Halpin, David M. G., et al. “Peak Expiratory Flow as an Endpoint for Clinical Trials in Asthma: A Comparison with FEV 1 .” Respiratory Research, vol. 20, no. 1, July 2019, p. 159. EBSCOhost, https://doi.org/10.1186/s12931-019-1119-6.

APA

Halpin, D. M. G., Meltzer, E. O., Pisternick-Ruf, W., Moroni-Zentgraf, P., Engel, M., Zaremba-Pechmann, L., Casale, T., & FitzGerald, J. M. (2019). Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV 1 . Respiratory Research, 20(1), 159. https://doi.org/10.1186/s12931-019-1119-6

Chicago

Halpin, David M G, Eli O Meltzer, Wendelgard Pisternick-Ruf, Petra Moroni-Zentgraf, Michael Engel, Liliana Zaremba-Pechmann, Thomas Casale, and J Mark FitzGerald. 2019. “Peak Expiratory Flow as an Endpoint for Clinical Trials in Asthma: A Comparison with FEV 1 .” Respiratory Research 20 (1): 159. doi:10.1186/s12931-019-1119-6.